Mass General Brigham’s Maze Therapeutics MAZE Stock Holding History
Bought
Maintained
Sold
Other funds holding MAZE
Mass General Brigham's MAZE Position: Q3 2026 in Review
Mass General Brigham increased its Maze Therapeutics (MAZE) stake by 4% in Q3 2026, buying an estimated $268K and bringing the position to 249,636 shares worth $6.79M. The position accounts for 1.49% of the portfolio, ranked #6.
Mass General Brigham first reported a position in MAZE in Q4 2025 and has held it in 4 quarters since. The position peaked at $9.9M in Q4 2025. 158 funds tracked by Wall St. Rank hold MAZE as of Q3 2026.
- Mass General Brigham held 249,636 shares of Maze Therapeutics worth $6.79M as of Q3 2026.
- Mass General Brigham bought 9,642 Maze Therapeutics shares in Q3 2026, an estimated $268K.
- Maze Therapeutics made up 1.49% of Mass General Brigham's portfolio in Q3 2026, its #6 holding.
- Mass General Brigham first reported a position in Maze Therapeutics in Q4 2025 and has held it in 4 quarters since.
- Mass General Brigham's Maze Therapeutics position peaked at $9.9M in Q4 2025.
- 158 funds tracked by Wall St. Rank held Maze Therapeutics as of Q3 2026.
Based on Mass General Brigham's 13F filing for Q3 2026, filed 3 Nov 2026.